Von Willebrand's disease

New England Journal of Medicine

Volumn 375, Issue 21, 2016, Pages 2067-2080

  Leebeek, Frank W G ^a   Eikenboom, Jeroen C J ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ATORVASTATIN; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; INTERLEUKIN 11; RECOMBINANT VON WILLEBRAND FACTOR; RISTOCETIN; THALIDOMIDE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; ARGIPRESSIN[1 DEAMINO];

AUTOSOMAL INHERITANCE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DISEASE CLASSIFICATION; FAMILY HISTORY; HUMAN; HYPONATREMIA; HYPOTENSION; LABORATORY TEST; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; VON WILLEBRAND DISEASE; AGE; ALGORITHM; CLASSIFICATION; FEMALE; GENETICS; HEMORRHAGE; MALE; MENORRHAGIA; PHYSIOLOGY; VON WILLEBRAND DISEASES;

AGE FACTORS; ALGORITHMS; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMORRHAGE; HUMANS; MALE; MENORRHAGIA; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84997822641     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1601561     Document Type: Review

References (75)

1. Von Willebrand E. Hereditar pseudo-hemofili. Fin Lakaresallsk Handl 1926; 68: 87-112.
2. Springer TA. Von Willebrand factor, Jedi knight of the bloodstream. Blood 2014; 124:1412-25.
3. Zimmerman TS, Ratnoff OD, Powell AE Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's disease, with observations on combined deficiencies of antihemo-philic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971; 50:244-54.
4. Lenting PJ, Casari C, Christophe O.D., Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost 2012; 10:2428-37.
5. Nichols WL, Hultin MB, James A.H., et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
6. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69:454-9.
7. Sadler JE, Mannucci PM, Berntorp E, et al Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
8. Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167:453-65.
9. Batlle J, Pérez-Rodríguez A, Corrales I, et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): proposal for a new diagnostic paradigm. Thromb Haemost 2016; 115:40-50.
10. Castaman G, Goodeve A, Eikenboom J. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica 2013; 98:667-74.
11. Sadler JE, Budde U, Eikenboom J.C., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
12. Cuker A, Connors JM, Katz J.T., Levy BD, Loscalzo J. A bloody mystery. N Engl J Med 2009; 361:1887-94.
13. Sanders YV, Fijnvandraat K, Boender J., et al. Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding. Am J Hematol 2015; 90: 1142-8.
14. de Wee E.M., Sanders YV, Mauser-Bunschoten EP, et al. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108:683-92.
15. Silwer J. Von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973; 238:1-159.
16. Sanders YV, de Wee EM, Meijer K, et al. Von Willebrand disease in the Netherlands: the WiN study. Ned Tijdschr Geneeskd 2014; 158:A6518. (In Dutch.)
17. Veyradier A, Boisseau P, Fressinaud E., et al. A laboratory phenotype/genotype correlation of 1167 French patients from 670 families with von Willebrand disease: a new epidemiologic picture. Medicine (Baltimore) 2016; 95(11):e3038.
18. Makris M, Federici AB, Mannucci P.M., et al. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia 2015; 21:338-42.
19. van Galen KPM, Mauser-Bunschoten EP, Leebeek FWG. Hemophilic arthropa-thy in patients with von Willebrand disease. Blood Rev 2012; 26: 261-6.
20. Federici AB, Bucciarelli P, Castaman G., et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood 2014; 1 23:4037-44.
21. de Wee E.M., Mauser-Bunschoten EP, Van Der Bom JG, et al. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost 2010; 8: 1492-9.
22. Kadir RA, Edlund M, Von Mackensen S. The impact of menstrual disorders on quality of life in women with inherited bleeding disorders. Haemophilia 2010; 16: 832-9.
23. Kadir RA, Economides DL, Sabin C.A., Owens D., Lee CA. Frequency of inherited bleeding disorders in women with menor-rhagia. Lancet 1998; 351:485-9.
24. Miller CH, Philipp CS, Stein S.F., et al. The spectrum of haemostatic characteristics of women with unexplained menor-rhagia. Haemophilia 2011; 17(1):e223-9.
25. De Wee E.M., Knol HM, Mauser-Bunschoten EP, et al. Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thromb Haemost 2011; 106:885-92.
26. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of von Willebrand disease. Thromb Res 2007; 120: Suppl 1: S17-20.
27. Stoof SCM, van Steenbergen HW, Zwagemaker A, et al. Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia 2015; 21: 505-1 2.
28. Kouides PA. An update on the management of bleeding disorders during pregnancy. Curr Opin Hematol 2015; 22: 397-405.
29. Rydz N, Grabell J, Lillicrap D., James PD. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia 2015; 21:636-41.
30. Sanders Y.V., Giezenaar MA, Laros-van Gorkom BAP, et al. Von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014; 12: 1066-75.
31. Sanders YV, Eikenboom J, de Wee EM, et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 2013; 11: 845-54.
32. Seaman CD, Yabes J, Comer D.M., Ragni MV. Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register. J Thromb Haemost 2015; 13: 1999-2003.
33. Hampshire DJ, Goodeve AC The International Society on Thrombosis and Haematosis von Willebrand Disease Database: an update. Semin Thromb Hemost 2011; 37:470-9.
34. Bowman M, Tuttle A, Notley C., et al. The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles. J Thromb Haemost 2013; 11: 512-20.
35. Goodeve A, Eikenboom J, Castaman G., et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109:112-21.
36. James PD, Notley C, Hegadorn C., et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 145-54.
37. Flood VH, Christopherson PA, Gill J.C., et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood 2016; 127: 2481-8.
38. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46:1836-44.
39. Smith NL, Chen MH, Dehghan A, et al Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121:1382-92.
40. Rydz N, Swystun LL, Notley C, et al The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood 2013; 121:5228-37.
41. Sanders Y.V., van der Bom JG, Isaacs A, et al. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. J Thromb Haemost 2015; 13: 956-66.
42. Tosetto A, Rodeghiero F, Castaman G., et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4:766-73.
43. Rodeghiero F, Tosetto A, Abshire T., et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Hae-most 2010; 8:2063-5.
44. Elbatarny M, Mollah S, Grabell J., et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the Merging Project. Haemophilia 2014; 20: 831-5.
45. Sanders Y.V., Groeneveld D, Meijer K., et al. Von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood 2015; 125: 3006-13.
46. Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L., Peyvandi F. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 2014; 20:147-53.
47. Flood VH, Gill JC, Morateck P.A., et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117(6):e67-74.
48. Bodó I, Eikenboom J, Montgomery R, et al. Platelet-dependent von Willebrand factor activity - nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13: 1345-50.
49. Gupta M, Lillicrap D, Stain A.M., Friedman KD, Carcao MD. Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease. Pediatr Blood Cancer 2011; 57:1081-3.
50. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108:3344-51.
51. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104:1009-21.
52. Roberts JC, Morateck PA, Christopherson PA, et al. Rapid discrimination of the phenotypic variants of von Willebrand disease. Blood 2016; 127:2472-80.
53. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101:2089-93.
54. Gudmundsdottir BR, Marder VJ, Onundarson PT. Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction. J Thromb Haemost 2007; 5: 274-81.
55. Siew DA, Mangel J, Laudenbach L., Schembri S, Minuk L. Desmopressin responsiveness at a capped dose of 15 μg in type 1 von Willebrand disease and mild hemophilia A. Blood Coagul Fibrinolysis 2014; 25:820-3.
56. Leissinger C, Carcao M, Gill J.C., Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia 2014; 20:158-67.
57. Stoof SCM, Cnossen MH, de Maat MPM, Leebeek FWG, Kruip MJHA. Side effects of desmopressin in patients with bleeding disorders. Haemophilia 2016; 22: 39-45.
58. Castaman G, Lethagen S, Federici A.B., et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111:3531-9.
59. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10:243-9.
60. Borel-Derlon A., Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007; 5:1115-24.
61. Mannucci PM. Treatment of von Wille-brand's disease. N Engl J Med 2004; 351: 683-94.
62. Coppola A, Franchini M, Makris M., Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18(3): e173-87.
63. Mannucci PM, Kempton C, Millar C., et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 2013; 122: 648-57.
64. Gill JC, Castaman G, Windyga J., et al. Hemostatic efficacy, safety, and pharma-cokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015; 126:2038-46.
65. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16:Suppl 1:S23-6.
66. Abshire T. The role of prophylaxis in the management of von Willebrand disease: today and tomorrow. Thromb Res 2009; 124:Suppl 1:S15-9.
67. Abshire T, Cox-Gill J, Kempton C.L., et al. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. J Thromb Haemost 2015; 13:1585-9.
68. Kouides PA, Byams VR, Philipp C.S., et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145: 21 2-20.
69. Chi C, Huq FY, Kadir RA Levonor-gestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception 2011; 83:242-7.
70. Ragni MV, Machin N, Malec L.M., et al. Von Willebrand factor for menorrhagia: a survey and literature review. Haemophilia 2016; 22:397-402.
71. James AH, Konkle BA, Kouides P, et al Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia 2015; 21:81-7.
72. van Galen K.P., Engelen ET, Mauser-Bunschoten E.P., van Es RJ, Schutgens RE. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev 2015; 12: CD011385.
73. Ragni MV, Novelli EM, Murshed A, Merricks E.P., Kloos MT, Nichols TC. Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A. Thromb Haemost 2013; 109:248-54
74. Ragni MV, Jankowitz RC, Jaworski K, Merricks EP, Kloos MT, Nichols TC. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost 2011; 106: 641-5
75. Engelen ET, van Galen KP, Schutgens RE. Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. Haemophilia 2015; 21:419-29.